For the first time, a research team at Lund University in Sweden has successfully reprogrammed mouse and human skin cells into immune cells called dendritic cells.
The process is quick and effective, representing a pioneering contribution for applying direct reprogramming for inducing immunity. Importantly, the finding opens up the possibility of developing novel dendritic cell-based immunotherapies against cancer.
Our so-called dendritic cells function as the immune system’s sentinels. Their task is to scan our tissues for foreign particles, such as bacteria, viruses or cancer cells, and to devour them. They subsequently break down the particles into smaller pieces, known as antigens, and present them on the surface to the immune system’s killer cells (T-cells). In this way, the killer cells learn which infectious agents and cancer cells they are to search for and kill.
Due to these key features, dendritic cell-based strategies have been tested to treat cancer patients. However, cancer can affect the dendritic cells in such a way that they get lost or become dysfunctional. We therefore need to find new ways of generating dendritic cells for every patient. Now, for the first time, a research team in Lund has succeeded in obtaining dendritic cells by a process called direct reprogramming. They have identified three essential proteins (PU.1, IRF8 and BATF3) that are required and sufficient to change the identity of mouse cells to make them become dendritic cells instead. They have also confirmed that the same protein cocktail reprograms human skin-derived cells to dendritic cells. This study is now published and highlighted in the cover of the journal Science Immunology.
“From a tissue section taken from the skin, we can cultivate millions of cells and reprogram them to dendritic cells in a process that takes only nine days”, says Filipe Pereira, the leader of the research team that conducted the study.
“Our study has shown that reprogrammed cells have the ability to effectively capture and present antigens to killer cells in the same way as ‘natural’ dendritic cells.” The researchers can even direct the induced dendritic cells towards a particular target by presenting the right antigen to them in a test tube, before introducing the cells into the organism. This finding opens up future possibilities to develop new strategies for immunotherapy against solid tumours and blood cancers, beyond the treatments currently available.
“This represents an excellent opportunity to merge the fields of cellular reprogramming and cancer immunotherapy. Generating dendritic cells employing direct cell reprogramming is very attractive from a therapeutic perspective: our studies may be useful in the clinic for generation of patient-specific dendritic cells”, according to Filipe Pereira.
Cancer immunotherapy employs the cellular components of a persons’ immune system to fight cancer and it was awarded with the Nobel Prize in Physiology or Medicine this year. By using reprogrammed dendritic cells the probability of rejection by the organism is lower as these cells can be generated from the skin of each individual patient.
“Tumours often undergo a number of mutations, developing into a heterogeneous entity, which makes it more difficult for the immune system to identify them as a threat. In a more creative perspective, we now want to explore the process of dendritic cell reprogramming to develop a cancer gene therapy. We are aiming at injecting the three reprogramming proteins straight into the tumour forcing it to present their own tumour-specific antigens. This allows the activation of the killer cells against tumour cells and may lead to their elimination. We have named this concept TrojanDC in an analogy with Homero’s Trojan horse. The great potential of this technology for cancer treatment lead us to start a new company together with Lund University for the development of this concept into a product that hopefully will reach cancer patients one day”, says Filipe Pereira.
“Additionally, our studies open up the possibility of reprogramming other dendritic cell sub-types taking advantage of their distinct functional features. A better understanding of the mechanisms that determine the identity of immune sentinels and of how to use this knowledge to reprogram other cell types into dendritic cells could make these patient-specific cells useful in the clinic”, concludes Filipe Pereira.
Learn more: WATCH: A code for reprogramming immune sentinels
The Latest on: Immunotherapies
via Google News
The Latest on: Immunotherapies
- Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cellson January 23, 2020 at 2:12 am
Our studies provide a strategy to augment the anti-tumor efficacy of iNKT cell-based immunotherapies via promoting their lipid biosynthesis. Recent studies demonstrate a link between cellular ...
- BHF announces shortlist for £30m research prize at start of defining decade for CVDon January 22, 2020 at 9:24 pm
A 'google map' of atherosclerosis to find and develop immunotherapies against heart attack and stroke also makes the shortlist, along with a project harnessing new technologies - including AI and ...
- BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicineon January 22, 2020 at 5:25 pm
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announced today ...
- Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of canceron January 22, 2020 at 6:53 am
This knowledge provides important insight for the choice and design of therapeutically successful virus-based immunotherapies. We investigated which of the most common cell death pathways (illustrated ...
- Genialis and Oncologie Collaborate on Precision Medicine Initiative in Gastric Canceron January 22, 2020 at 5:54 am
Genialis, a leader in applied data science for the development of precision medicines, today announced a collaborative partnership with Oncologie, an international, clinical-stage biopharma developing ...
- Houston pharma co. to sell facility to MD Anderson Cancer Centeron January 22, 2020 at 5:33 am
M.D. Anderson will acquire a new facility and employees from a Houston-based biopharmaceutical company, but it will continue to manufacture the company's cell therapy programs.
- Oncolytics Biotech: A Small But Very Promising Cancer Player In 2020on January 22, 2020 at 3:46 am
Instead, they amplify and accelerate the immune system in the patient’s body to identify and then destroy the tumor cells. The market opportunity would have been even higher if immunotherapies would ...
- Korean VCs pile into PDC*line to bankroll NSCLC vaccine trialon January 22, 2020 at 3:33 am
Franco-Belgian biotech PDC*line is developing anticancer immunotherapies based on an allogeneic therapeutic cell line of plasmacytoid dendritic cells. PDC*line secured access to the cells as a spinout ...
- OncoSec Secures Phesi ClinSite™ License to Select Clinical Trial Investigator Siteson January 22, 2020 at 3:30 am
Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced that OncoSec Medical ...
via Bing News